Buchler Tomas, Harland Stephen J
Department of Oncology, University College London Hospital, London, United Kingdom.
Indian J Urol. 2007 Jan;23(1):55-60. doi: 10.4103/0970-1591.30269.
Significant progress has been achieved in chemotherapy for hormone-resistant prostate cancer (HRPC) in the last five years. Although the disease was long considered to be chemoresistant, docetaxel-based regimens in particular have been shown to both palliate symptoms and prolong survival in HRPC patients. Docetaxel is now considered the best available chemotherapy for prostate cancer progressing on first-line hormonal treatment. Other cytotoxics including mitoxantrone, anthracyclines, vinorelbin and vinblastine can alleviate symptoms and improve progression-free survival in HRPC without affecting overall survival. The survival benefit from chemotherapy seen in randomized studies has been small or nonexistent. Results of a recent trial suggest that the survival benefit may have been underestimated as a result of crossover from the less active to the active arm.
在过去五年中，激素抵抗性前列腺癌（HRPC）的化疗取得了重大进展。尽管长期以来人们一直认为这种疾病对化疗耐药，但特别是基于多西他赛的治疗方案已被证明既能缓解HRPC患者的症状，又能延长其生存期。多西他赛现在被认为是一线激素治疗进展性前列腺癌的最佳可用化疗药物。其他细胞毒性药物，包括米托蒽醌、蒽环类药物、长春瑞滨和长春碱，可以缓解HRPC的症状并改善无进展生存期，但不影响总生存期。在随机研究中观察到的化疗对生存期的益处很小或不存在。最近一项试验的结果表明，由于患者从疗效较差的治疗组交叉到疗效较好的治疗组，生存期的益处可能被低估了。
